Cambridge Cognition highlights positive Cantab results

New FDA-approved schizophrenia treatment shows promise in clinical trials

Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval of Cobenfy (KarXT), a new treatment for schizophrenia.

Recent research published in The American Journal of Psychiatry showcases the use of Cambridge Cognition’s Cantab product in two phase 3 clinical trials involving patients with schizophrenia.

Cobenfy, targeting M1 and M4 muscarinic receptors, represents a significant advancement. Unlike traditional antipsychotics, which block dopamine receptors, this approach effectively reduces both positive and negative symptoms of schizophrenia.

CANTAB digital assessments provide accurate and objective measures of cognitive function in clinical trials. Bristol Myers Squibb used data from Cantab cognitive assessments for a post-hoc analysis of two phase 3 trials.

The study, titled ‘The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia,’ revealed improvement in patients with pre-specified cognitive impairments after treatment with Cobenfy.

Rob Baker, Chief Operating Officer and Joint Managing Director at Cambridge Cognition, commented: “This is an important milestone in schizophrenia treatment’s history, and we are pleased to have been able to play a part.”

He added: “Importantly, this analysis evidences how our digital assessment technologies can streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments in schizophrenia.”

Cambridge Cognition believes these findings highlight Cantab’s effectiveness in measuring cognitive performance improvements.

The company remains committed to assisting pharmaceutical firms in leveraging cutting-edge study designs and digital data capture technologies for impactful research.

The successful use of Cantab assessments in Bristol Myers Squibb’s trials underscores its potential in developing new schizophrenia treatments.

This latest development underscores the ongoing commitment to enhancing treatments for patients with neurological disorders.